MedTrace Logo

The Effect of Botulinum Toxin A on Headache Attributed to TMD

NCT03346252 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-10-04

No results posted yet for this study

Summary

This study will evaluate the effect of of botulinum toxin on the treatment of Headache Attributed to TMD.

Conditions

  • Secondary Headache Disorder

Interventions

DRUG

Botulinum Toxin type A

All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires. In addition, they will undergo 3 cycles of treatment, each 12 weeks apart.

Sponsors & Collaborators

  • State University of New York at Buffalo

    lead OTHER

Principal Investigators

  • Yoly M Gonzalez-Stucker, DDS, MS, MPH · University at Buffalo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-08
Primary Completion
2021-03-15
Completion
2021-03-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03346252 on ClinicalTrials.gov